AbbVie enters $90m agreement to develop multiple myeloma immunotherapy

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/undefined undefined)
(Image: Getty/undefined undefined)

Related tags: Immunotherapy, AbbVie, Multiple myeloma, Bispecific antibodies, Antibody, Biologics, Immune system

AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.

Through the agreement, the companies will use Teneobio’s anti-CD3 platform to develop TNB-383B, a B-cell maturation antigen (BCMA) targeting immunotherapy treatment.

TNB-383B is a bispecific antibody that targets both BCMA and CD3, using the body’s immune system to target and kill the surface protein BCMA on tumor cells. BCMA proteins support the survival of multiple myeloma cells.

Per the agreement, TeneoOne, an affiliate of Teneobio focused on developing biologics, will receive an upfront payment of $90m (€79.8m) to continue developing TNB-383B through Phase I clinical trials.

AbbVie will hold the right to acquire TeneoBio’s biologic development sect TeneoOne, for global development and commercialization of the therapy candidate.

Mohit Trikha, VP and head of oncology early development at AbbVie, said in a statement, "Multiple myeloma is one of the most common hematological cancers and an area of significant medical need. Teneobio's novel approach to T-cell redirection with TNB-383B has the potential to be a treatment option that may offer new hope for myeloma patients."

Teneobio is expected to begin the clinical program for TNB-383B in the first half of 2019.

Therapies used to target BCMA proteins for the treatment of multiple myeloma have been developed before, but many of these drug candidates​ were chimeric antigen receptor (CAR) T-cell therapies. Bluebird Bio and Celgene entered an agreement​ in March 2018 to co-develop a BCMA CAR-T cell therapy for the treatment of multiple myeloma.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars